HomeIngredientIntegrated gut microbiome and metabolome analyses reveals an inconsistent dose effect of a tuna oil with more higher docosahexaenoic acid content on intestinal dysbiosis and metabolic disorders in high-fat diet-fed mice

Integrated gut microbiome and metabolome analyses reveals an inconsistent dose effect of a tuna oil with more higher docosahexaenoic acid content on intestinal dysbiosis and metabolic disorders in high-fat diet-fed mice

April 4, 2022

J Sci Food Agric. 2022 Apr 3. doi: 10.1002/jsfa.11908. Online ahead of print.

ABSTRACT

BACKGROUND: The health benefits of tuna oil, which is different from fish oil commonly studied, and its higher docosahexaenoic acid (DHA) content, have attracted much scientific attention in the recent years. In this study, a prepared tuna oil with more higher DHA (HDTO) content was employed. It was the first to integrate microbiome and metabolome from the perspective of dose-effect to investigate the influence of HDTO on gut dysbiosis and metabolic disorders in diet-induced obese mice.

RESULTS: HDTO was effective in reversing the high-fat-diet-induced metabolic disorders and altering the gut microbiota composition and function, but these effects did not show a uniform dose-dependent. The flora and metabolites that were targeted to be regulated by HDTO supplementation were Prevotella, Bifidobacterium, Olsenella, glycine, L-aspartate, L-serine, L-valine, L-isoleucine, L-threonine, L-tyrosine, glyceric acid, glycerol, butanedioic acid, and citrate, respectively. Functional pathway analysis revealed that the alterations of these metabolic biomarkers were associated with six main metabolic pathways: glycine, serine, and threonine metabolism; glycerolipid metabolism; glyoxylate and dicarboxylate metabolism; alanine, aspartate, and glutamate metabolism; aminoacyl-tRNA biosynthesis, and the citrate cycle (TCA cycle).

CONCLUSION: Various doses of HDTO could attenuate endogenous disorders to varying degrees through regulating multiple perturbed pathways to the normal state. This explicit dose research for novel fish oil with high-DHA will provide a valuable reference for those seeking to exploit its clinical therapeutic potential. This article is protected by copyright. All rights reserved.

PMID:35368101 | DOI:10.1002/jsfa.11908

Tags:, , , , , , , , ,

Related Posts

About The Author

Patrick Blanchard MD

Meet Dr. Blanchard Dr. Blanchard’s medical practice is an embodiment of Integrative health which brings conventional and complementary approaches together in a coordinated way. Conveniently located in sunny Florida and over the internet with ValiseMD’s secure HIPPA compliant telXmed servers. Since 1994, patients with a wide range of challenging medical problems have achieved optimum health using the best of natural medicine, judiciously combined with high-tech innovations. Breakthroughs are often achieved even after patients have consulted mainstream specialists and holistic practitioners. Dr. Blanchard is founder and CEO of ValiseMD, Inc. He is board certified in Family Medicine since 1994 and awarded Fellow of the American Academy of Family Physicians in 2001. He received the ‘Teacher of the Year’ award from the University of Kansas School of Medicine at completion of his residency in Family Medicine. He completed a fellowship at Wake Forest University in the field of vascular neurosonology. He holds a medical patent in the field of Gastroenterology. He holds an unrestricted license to practice medicine and surgery in Florida. He started his medical career as a Emergency Medical Technician, then as a Paramedic and later a Medical Doctor.